Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors ; volume:10 ; number:1 ; day:11 ; month:1 ; year:2024 ; pages:1-11 ; date:12.2024
Cardio-Oncology ; 10, Heft 1 (11.1.2024), 1-11, 12.2024
- Urheber
-
Perelman, Moran Gvili
Brzezinski, Rafael Y.
Waissengrin, Barliz
Leshem, Yasmin
Bainhoren, Or
Rubinstein, Tammi Arbel
Perelman, Maxim
Rozenbaum, Zach
Havakuk, Ofer
Topilsky, Yan
Banai, Shmuel
Wolf, Ido
Laufer-Perl, Michal
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s40959-023-00199-6
- URN
-
urn:nbn:de:101:1-2024032512211985064616
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:46 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Perelman, Moran Gvili
- Brzezinski, Rafael Y.
- Waissengrin, Barliz
- Leshem, Yasmin
- Bainhoren, Or
- Rubinstein, Tammi Arbel
- Perelman, Maxim
- Rozenbaum, Zach
- Havakuk, Ofer
- Topilsky, Yan
- Banai, Shmuel
- Wolf, Ido
- Laufer-Perl, Michal
- SpringerLink (Online service)
Ähnliche Objekte (12)
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review
Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential
Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetes: A Scoping Review
Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors
Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use
Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure
Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Comparing Trial and Real World Use (Study Protocol)
Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction
Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review
Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential
Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetes: A Scoping Review
Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors
Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use
Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure
Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Comparing Trial and Real World Use (Study Protocol)
Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction
Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review
Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential
Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetes: A Scoping Review
Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors
Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use
Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure
Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Comparing Trial and Real World Use (Study Protocol)
Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction
Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders